Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Authors
Keywords
-
Journal
LANCET NEUROLOGY
Volume 21, Issue 8, Pages 693-703
Publisher
Elsevier BV
Online
2022-07-14
DOI
10.1016/s1474-4422(22)00209-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
- (2021) Ludwig Kappos et al. JAMA Neurology
- Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
- (2021) Tim Spelman et al. JAMA Neurology
- Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
- (2021) Steve Simpson-Yap et al. NEUROLOGY
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis
- (2019) Justin M. Honce et al. NEUROLOGY
- Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
- (2019) Katharine Harding et al. JAMA Neurology
- Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
- (2019) M. Boremalm et al. EUROPEAN JOURNAL OF NEUROLOGY
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
- (2018) S. G. Berntsson et al. ACTA NEUROLOGICA SCANDINAVICA
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
- (2018) Mathias Granqvist et al. JAMA Neurology
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
- (2016) M. Vågberg et al. ACTA NEUROLOGICA SCANDINAVICA
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
- (2016) Pierre de Flon et al. NEUROLOGY
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
- (2015) D. M. Hartung et al. NEUROLOGY
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now